BIOLIFE SOLUTIONS INC

BioLife Solutions, Inc. (NASDAQ: BLFS) is a life sciences company that develops, manufactures, and markets bioproduction products and services designed to improve quality and reduce risk in biologic manufacturing, distribution, and transportation for the cell and gene therapy industry. The company's website is www.biolifesolutions.com.

The company operates as a single bioproduction products and services business supporting multiple steps in the biologic material manufacturing and delivery process. BioLife's portfolio focuses on biopreservation media and cell processing products, leveraging in-house expertise in cryobiology and cell and gene therapy workflows. The company's primary offerings include proprietary biopreservation media products such as HypoThermosol FRS and CryoStor Freeze Media, which are formulated to mitigate preservation-induced cell damage and extend shelf-life of biologic materials. Additional products include human platelet lysate media, cryogenic containers, automated cell-processing fill machines, and the ThawSTAR line of automated thawing devices that control temperature and timing during the thawing process.

BioLife's biopreservation media products are serum-free, protein-free, fully defined formulations manufactured under current Good Manufacturing Practices. The company maintains two independent cGMP clean room production suites in Bothell, Washington for manufacturing sterile biopreservation media and one cGMP clean room in Indianapolis, Indiana for manufacturing human platelet lysate media. The company employs 155 full-time team members as of December 31, 2025.

Revenue is geographically distributed with approximately 80 percent from the United States, 14 percent from Europe, Middle East, and Africa, and six percent from other regions. Sales occur through direct sales and third-party distribution channels, with distributor sales representing approximately 34 percent of revenue. The company's products are utilized in several hundred active clinical trials worldwide and have been cross-referenced over 750 times in FDA Type II Master Files by customers.

Recent corporate activity includes the divestiture of multiple business units including SAVSU, Custom Biogenic Systems, SciSafe, and Global Cooling, while acquiring the remaining 90 percent stake in PanTHERA CryoSolutions, which holds patented Ice Recrystallization Inhibitor technology intended to enhance the company's core biopreservation capabilities.